Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 9/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.39 |
| ▸ | F7 | P08709 | 3/20 | 0.39 |
| ▸ | F3 | P13726 | 3/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891689 | 1.00 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL1107677 | 0.91 | GCK (0.44) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL1107663 | 0.91 | GCK (0.44) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL1107678 | 0.90 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL1107674 | 0.90 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL12742943 | 0.80 | GCK (0.48) | GCK | |
| SCHEMBL12594260 | 0.76 | GCK (0.47) | GCK | |
| SCHEMBL12742920 | 0.76 | GCK (0.54) | GCK | |
| SCHEMBL1107566 | 0.76 | ALDH1A1 (0.45) | F2PRSS1P2RX3P2RX2GCK | |
| SCHEMBL1107682 | 0.74 | GCK (0.64) | P2RX3P2RX2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | PDE4D 1606/4885PDE4A 1377/4885PDE4B 1253/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | PDE4D 1824/4885PDE4A 1590/4885PDE4B 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.